2型糖尿病治疗药物的药物基因组学研究进展  

Advances in pharmacogenomics for the treatment of type 2 diabetes

作　　者：马玉龙 李亚龙 胡晓霞[2] 金更学(综述) 刘欣跃(审校)[1] MA Yulong;LI Yalong;HU Xiaoxia;JING Gengxue;LIU Xinyue(Medical Center of Laboratory,the Second Hospital of Lanzhou University,Lanzhou,Gansu 730000,China;Department of Geriatrics,the Second Hospital of Lanzhou University,Lanzhou,Gansu 730000,China;Department of Endocrinology,the Second Hospital of Lanzhou University,Lanzhou,Gansu 730000,China)

机构地区：[1]兰州大学第二医院检验医学中心,甘肃兰州730000 [2]兰州大学第二医院老年病科,甘肃兰州730000 [3]兰州大学第二医院内分泌科,甘肃兰州730000

出　　处：《国际检验医学杂志》2025年第3期349-353,共5页International Journal of Laboratory Medicine

基　　金：甘肃省自然科学基金项目(22JR5RA953、23JRRA0999、23JRRA0958);兰州大学第二医院“萃英科技创新计划”项目(CY2023-MS-B12)。

摘　　要：降糖药物是2型糖尿病患者治疗的重要手段,但在临床治疗中,效果不佳、无效乃至药物不良反应皆时有发生。随着药物基因组学的发展,对个体遗传变异和药物剂量与治疗反应之间的关联逐渐清晰,由此患者获得了更好的疗效并减少了不良反应。该文聚焦于降糖药物,综述其最新的药物基因组学研究进展,为个体化治疗2型糖尿病并预防相应并发症直至实现精准医学提供参考。Hypoglycemic drugs are an important means of treatment for patients with type 2 diabetes.However,poor,ineffective and even adverse drug reactions often occur in clinical treatment.With the development of pharmacogenomics,the link between individual genetic variation and drug dose and treatment response is becoming clearer,resulting in better efficacy and fewer adverse reactions for patients.This article focuses on hypoglycemic drugs and reviews the latest advances in pharmacogenomics,so as to provide references for individualized treatment of type 2 diabetes and prevention of corresponding complications until the realization of precision medicine.

关 键 词：2型糖尿病 药物基因组学 精准医学 

分 类 号：R587.1[医药卫生—内分泌]